Southern Medical Journal · 2006 · 24 citations · 43 references
PharmacyPharmacoeconomicsPharmacotherapyBone MetabolismCost-effectiveness AnalysisCost-utility AnalysisCost-effectiveness ThresholdsFracture PreventionFracture RiskOsteoporosisOsteoporosis PharmacotherapyPharmacoepidemiologyBone DensitometryCost-effectivenessFracturesIncremental Cost EstimationOsteoporotic FracturesPostmenopausal Osteoporosis TreatmentRelative Risk ReductionTreatment With Bisphosphonates
BACKGROUND: Comparing the cost-effectiveness of various antiosteoporotic drugs has not been defined. METHODS: We determined the cost-effectiveness of calcitonin, raloxifene, bisphosphates and PTH in a base-case cohort of women aged 65 or older with osteoporosis. After bone densitometry, women were stratified into groups of treatment or no treatment. Our outcome goal was a value of dollars 100,000 or less per quality-adjusted life years (QALY). A sensitivity analysis varied nonvertebral fracture reduction and compliance between the two most effective strategies to test various cost per QALY thresholds. RESULTS: Bisphosphonates displayed the most favorable incremental cost saving and prevented more fractures in our base-case analysis. In a sensitivity analysis, virtually all values of bisphosphonates were under dollars 100,000 per QALY and parathyroid hormone (PTH) was between dollars 100,000 and dollars 200,000 per QALY. CONCLUSIONS: Only bisphosphonates are cost-effective for fracture prevention in osteoporotic women aged 65 or older and this economic advantage is also maintained in subsets who have a lower relative risk of future fracture.
43
Risk Factors for Hip Fracture in White Women
Steven R. Cummings, Michael C. Nevitt, Warren S. Browner et al. · New England Journal of Medicine · 1995 · 3.6K citations · Full text